Regeneron Melanoma Trial Miss Spurs BofA Hold, Stock Drops 5.7%
2h ago|4 min read1Standard
Fazen Markets Editorial Desk
Collective editorial team · methodology
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Bank of America reiterated its buy rating on Regeneron Pharmaceuticals following the company's announcement of a trial miss for its drug Libtayo in a specific melanoma setting. Investing.com reported the news on May 18, 2026. The stock price immediately fell 5.7% in pre-market trading, reflecting investor disappointment. Regeneron's market capitalization declined by roughly $5.1 billion on the news.
The importance of this trial outcome is anchored in Regeneron's strategic reliance on expanding its immunotherapy portfolio beyond its initial successes. Regeneron's EYLEA franchise for eye diseases faces mounting biosimilar pressure, making the success of Libtayo a critical pillar for future growth. The last significant Libtayo setback occurred in June 2024, when a combination trial in non-small cell lung cancer failed to hit its primary endpoint, sending shares down 8% over two days.
The current macro backdrop for biotech remains challenging, with the iShares Biotechnology ETF (IBB) still 18% below its 2021 highs, as investors prioritize profitability over speculative pipeline assets. The trigger for this specific event was the release of top-line results from a Phase 3 study evaluating Libtayo as an adjuvant treatment for stage II to IV resectable melanoma. The trial did not meet its primary endpoint of recurrence-free survival, halting a potential new indication.
This miss is particularly significant because the adjuvant melanoma market is dominated by Merck's Keytruda. Gaining a foothold in this established market was seen as a key commercial opportunity for Libtayo to diversify its revenue base beyond its approved uses in skin and lung cancers.
The immediate financial impact of the trial miss was a $5.1 billion erosion in Regeneron's market value, with the stock dropping from $1,050 pre-announcement to approximately $990. This 5.7% single-day decline sharply underperformed the broader Nasdaq Biotechnology Index, which was down only 0.3% over the same period.
| Metric | Pre-Announcement | Post-Announcement | Change |
|---|---|---|---|
| REGN Stock Price | ~$1,050 | ~$990 | -5.7% |
| Market Cap | ~$90.1B | ~$85.0B | -$5.1B |
Libtayo generated $2.4 billion in global sales for Regeneron in 2025, representing about 16% of the company's total product revenue. Analysts had projected the new melanoma indication could have contributed an incremental $800 million to $1.2 billion in peak annual sales. The stock's forward price-to-earnings ratio compressed from 19.5x to 18.3x following the announcement, reflecting a de-risking of future growth estimates.
The primary second-order effect is a strengthened competitive moat for Merck & Co. (MRK). With the failure of a credible challenger in adjuvant melanoma, Merck's Keytruda faces one less threat to its dominant market position. This could support Merck's premium valuation, which trades at a forward P/E of 22x versus Regeneron's 18.3x.
The clear counter-argument, reflected in BofA's maintained buy rating, is that Libtayo's core revenue base in advanced cutaneous squamous cell carcinoma and non-small cell lung cancer remains untouched. The company's diversified pipeline, including promising assets like next-gen cholesterol drug Evkeeza and bispecifics, mitigates the impact of this single trial failure. Institutional flow data indicates that while fast-money hedge funds were sellers on the headline, several large long-only healthcare funds used the dip to add to positions, betting on the broader pipeline's execution.
Immediate sector beneficiaries include other checkpoint inhibitor developers like Gilead Sciences (GILD) and Bristol-Myers Squibb (BMY), who may see reduced competitive pressure in adjacent oncology markets. The trial outcome also serves as a reminder of the binary risks in oncology development, potentially shifting incremental investor capital towards platform technology biotechs over single-asset oncology plays.
The immediate catalyst for Regeneron is its second-quarter earnings call, scheduled for July 29, 2026. Management will provide detailed commentary on the trial data and any strategic pivots for the Libtayo program. Investors will listen for updates on enrollment for other pivotal Libtayo studies, including one in advanced cervical cancer.
A key technical level to watch for REGN shares is the $950 support zone, a level that held during the June 2024 sell-off. A sustained break below that level could signal a deeper re-rating. The next major clinical catalyst for the broader oncology sector is the European Society for Medical Oncology (ESMO) Congress in mid-September 2026, where detailed data from competing immuno-oncology studies will be presented.
Market focus will also shift to the FDA's Prescription Drug User Fee Act (PDUFA) action date for Regeneron's high-dose EYLEA, expected in late Q3 2026. Positive regulatory action there could offset the negative sentiment from the melanoma trial miss, providing a separate valuation catalyst.
The immediate impact on a broad biotech ETF like the IBB or XBI will be muted, as Regeneron is one holding among hundreds. However, the event reinforces a sector-wide pattern of high clinical trial volatility. It may contribute to a risk-off sentiment for mid-cap biotechs with similar binary, late-stage oncology catalysts, potentially suppressing valuations across that sub-sector until the next major positive readout.
The magnitude of Regeneron's 5.7% drop is moderate compared to historic failures. In March 2023, Gilead Sciences' Trodelvy failed a lung cancer trial, leading to a 12% single-day decline. In October 2022, Bristol-Myers Squibb's Opdivo/Yervoy combo missed in kidney cancer, causing a 7% drop. The smaller relative drop for Regeneron suggests the market had not fully priced in success for this specific Libtayo expansion, viewing it as a lower-probability event.
Overall success rates for oncology drugs in Phase 3 development are approximately 45%, according to a 2021 analysis by biotechnology industry group BIO. However, success rates vary dramatically by modality and target. For monoclonal antibodies like Libtayo in solid tumors, the historical success rate is closer to 50%, making any individual failure a statistically probable, yet financially significant, event.
BofA's reiterated buy rating reflects a long-term view on Regeneron's diversified pipeline, but the trial miss exacts a tangible cost on Libtayo's growth potential.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.